Crescent Biopharma to Present at June Investor Conferences
Rhea-AI Summary
Crescent Biopharma (Nasdaq: CBIO), a clinical-stage biotechnology company focused on cancer therapies, will present at two June 2026 investor conferences.
Management will host fireside chats at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs Global Healthcare Conference on June 8, with live webcasts and 90-day replays.
Positive
- None.
Negative
- None.
News Market Reaction – CBIO
In the Jun 3 session, CBIO gained 5.73%, reflecting a notable positive market reaction. Argus tracked a trough of -12.1% from its starting point during tracking. Our momentum scanner triggered 33 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 21 | ASCO trial update | Positive | +2.5% | ASCEND Phase 1/2 ASCO Trial-in-Progress poster for CR-001 bispecific. |
| May 12 | Inducement option grants | Neutral | +6.2% | Stock option inducement awards to five non-executive employees. |
| May 06 | May investor conferences | Neutral | -0.1% | Management presentations at three May healthcare and oncology conferences. |
| Apr 29 | Q1 2026 earnings | Positive | +6.8% | Q1 2026 results and pipeline update with cash runway into 2028. |
| Apr 24 | Inducement option grants | Neutral | +1.4% | Inducement option grants for two non-executive employees. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including trial, financing and earnings updates, has generally coincided with positive or stable next-day price reactions.
Over the past months, Crescent Biopharma reported Q1 2026 results on April 29, 2026 with $189.2 million in cash, which saw a 6.83% next-day gain. Multiple inducement option grants in April and May produced modest positive reactions. Scientific and visibility events—such as the ASCEND Phase 1/2 ASCO Trial-in-Progress announcement on May 21, 2026 and May investor conference presentations—were followed by small gains or flat trading. Today’s June conference appearances fit this pattern of ongoing visibility-building rather than a discrete clinical or financial inflection.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in June:
- 2026 Jefferies Global Healthcare Conference, fireside chat on Wednesday, June 3, 2026 at 4:20 p.m. ET in New York
- Goldman Sachs 47th Annual Global Healthcare Conference, fireside chat on Monday, June 8, 2026 at 8:40 a.m. ET in Miami
A live webcast of each presentation will be available in the Investors section of Crescent's website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Contacts
Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019
